Journal of Heavy Metal Toxicity and Diseases
ISSN: 2473-6457

Open access Perspective

Heavy Metal Exposure and Cancer Therapy: An Evolving Relationship

Morgan Brown*

Department of Medicine, Wisconsin University, United States

INTRODUCTION

Heavy metals, such as arsenic, cadmium, lead, mercury, and chromium, are toxic environmental contaminants that pose significant risks to human health. Exposure to these metals, whether through industrial activities, contaminated water, food, or air, can result in a range of health issues, including neurological damage, organ dysfunction, and cancer. However, in the realm of cancer treatment, certain metals have also garnered attention due to their therapeutic potential. This article explores the complex relationship between heavy metal exposure and cancer therapy, examining both the toxic effects of metals and their growing role in anticancer treatments.

DESCRIPTION

Heavy metals are known to be carcinogenic, meaning they can initiate or promote cancer development by causing DNA damage, inducing inflammation, and disrupting cellular processes. Long-term exposure to metals like arsenic, cadmium, and chromium has been associated with increased risks of several cancers, including lung, bladder, and skin cancer. Cadmium exposure has been associated with lung cancer and prostate cancer. It contributes to carcinogenesis by inducing oxidative stress and disrupting cell signaling pathways, which can lead to abnormal cell growth. Although lead is not as commonly discussed in cancer research as other metals, evidence suggests that chronic exposure may contribute to cancer risk, particularly in the kidneys and lungs. Lead interferes with DNA repair mechanisms and can activate pathways that promote tumor growth. While the toxic effects of heavy metals are well-documented, an intriguing aspect of cancer treatment is the use of certain metals as part of chemotherapy regimens. For example, metals like platinum and ruthenium have demonstrated promising anticancer properties, highlighting the dual role of heavy metals in both causing and treating cancer. One of the most well-known examples of heavy metals in cancer therapy is the use of platinum-based compounds, such as cisplatin, carboplatin, and oxaliplatin. This effect is especially effective against rapidly dividing cancer cells. These side effects are a direct result of the drug's heavy metal content and its interaction with normal, healthy cells, highlighting the potential dangers of using heavy metals in therapeutic settings. Ruthenium, a metal in the platinum group, has emerged as a promising alternative in cancer therapy. The primary concern with using heavy metals in cancer therapy is their toxicity. While platinum-based drugs are effective in killing cancer cells, they can also cause significant damage to normal cells, leading to long-term health issues. The development of more targeted therapies that can selectively deliver these drugs to cancer cells is an active area of research. Another issue with heavy metal-based therapies is the development of drug resistance. Cancer cells can adapt to the presence of chemotherapeutic agents, reducing their effectiveness over time. While the therapeutic use of heavy metals holds promise, the environmental exposure to these metals remains a critical public health concern. Pollution from industries, mining, and agriculture continues to expose populations to toxic levels of metals, contributing to an increased cancer burden.

CONCLUSION

Heavy metal exposure is a significant risk factor for cancer, with various metals contributing to the development and progression of tumors. However, some heavy metals, particularly platinum and ruthenium, have also shown promise as effective cancer therapies. While the use of heavy metals in chemotherapy offers potential benefits, challenges related to toxicity, drug resistance, and environmental exposure remain. Continued research into targeted therapies, metal-based drug delivery systems, and novel treatments will be critical in advancing the field of cancer therapy while minimizing the harmful effects of heavy metal exposure.

Received:	02-December-2024	**Manuscript No:**	ipjhmct-24-22054
Editor assigned:	04-December-2024	**PreQC No:**	ipjhmct-24-22054 (PQ)
Reviewed:	18-December-2024	**QC No:**	ipjhmct-24-22054
Revised:	23-December-2024	**Manuscript No:**	ipjhmct-24-22054 (R)
Published:	30-December-2024	**DOI:**	10.21767/2473-6457.24.6.52

Corresponding author Morgan Brown, Department of Medicine, Wisconsin University, United States, E-mail: m_78@edu.uk

Citation Brown M (2024) Heavy Metal Exposure and Cancer Therapy: An Evolving Relationship. J Heavy Met Toxicity Dis. 09:52.